Cost-effectiveness of caplacizumab in immune thrombotic thrombocytopenic purpura in the United States
{{output}}
Background: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening thrombotic microangiopathy. Caplacizumab is the only treatment approved by the European Medicines Agency and the US Food and Drug Administr... ...
